<DOC>
	<DOCNO>NCT02775539</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety mirabegron ( B3 adrenergic receptor agonist ) patient pulmonary hypertension secondary heart failure conduct randomized multicenter phase II placebo-controlled clinical trial .</brief_summary>
	<brief_title>Beta3 Agonist Treatment Chronic Pulmonary Hypertension Secondary Heart Failure</brief_title>
	<detailed_description>Pulmonary hypertension ( PH ) affect 60-80 % patient chronic heart failure ( HF ) critical impact prognosis . Currently , specific treatment approve indication . Experimental research , perform member consortium , demonstrate treatment B3 adrenergic receptor agonist produce beneficial effect pulmonary hemodynamics , right ventricular ( RV ) remodel pulmonary vascular proliferation translational pig model postcapillary PH . Mirabegron , oral B3AR agonist , currently approve different medical condition ( overactive bladder syndrome ) good safety profile . Our main objective evaluate efficacy safety mirabegron patient PH secondary HF . The objective evaluated conduct phase-2 randomize placebo-controlled clinical trial patient PH associate HF . Patients randomize 1:1 mirabegron placebo , dose titrate till 200 mg/day . Patients evaluate quality life questionnaire , blood analysis , ECG , echocardiography , 6-minute walk test , right heart catheterization ( RHC ) cardiac magnetic resonance ( CMR ) baseline 16 week treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Written inform consent ; &gt; 18 yearsold ; HF reduce preserved ejection fraction , accord definition European Society Cardiology guideline . Severe PH and/or combine postcapillary precapillary PH ( also know reactive outofproportion PH ) determine RHC show follow : Pulmonary arterial wedge pressure enddiastolic leave ventricular pressure ≥15 mmHg ; Mean PAP≥25 , : PVR≥3 UW and/or diastolic gradient≥7 mmHg Transpulmonary gradient≥12 . NYHA functional class IIIV ; On optimized evidencebased pharmacological treatment ; Stable clinical condition define change therapeutic regimen hospitalization 30 day precede recruitment current plan change therapy . Noncoronary cardiac surgery noncoronary percutaneous procedure within 12 month precede recruitment program ; Myocardial infarction coronary revascularization last 3 month , Myocardial resynchronization therapy initiate last 6 month ; Sinus tachycardia atrial fibrillation uncontrolled heart rate ( &gt; 100 bpm ) ; Uncontrolled hypertension ( PAS &gt; 180 PAD &gt; 110 mmHg ) symptomatic hypotension ( PAS &lt; 90 mmHg ) . Infiltrative myocardial disease . Expected survival &lt; 1 year due disease PH ; Severe renal failure ( GFR &lt; 30 mL/min/1.73 m2 haemodialysis ) ; Severe hepatic impairment ( serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3x upper limit normality screening ; cQT interval ECG &gt; 430 m male &gt; 450 ms female ; Concomitant use specific pulmonary vasodilator therapy ( i.e . endothelin receptor antagonist , phosphodiesterase 5 inhibitor , guanylate cyclase stimulators ) . Concomitant use digoxin , flecainide , propafenone , dabigatran , tricycle antidepressant , another strong inhibitor CYP2D6 ( exception betablockers ) . Significant obstructive lung disease ( FEV1/FVC &lt; 0.7 associated FEV1 &lt; 50 % predict value ) . Significant restrictive lung disease ( TLC &lt; 60 % ) . Participation another clinical trial . Female childbearing potential . Known hypersensitivity mirabegron excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Heart failure</keyword>
	<keyword>B3 adrenergic</keyword>
</DOC>